Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.

Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17. No abstract available.

PMID:
29984424
2.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.

Ann Hematol. 2018 May 27. doi: 10.1007/s00277-018-3365-y. [Epub ahead of print]

PMID:
29804268
3.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
4.

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM.

J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30. No abstract available.

PMID:
29708808
5.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

6.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Apr 5. pii: haematol.2017.185751. doi: 10.3324/haematol.2017.185751. [Epub ahead of print] No abstract available.

7.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

8.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

9.

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A.

Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. Review.

10.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.

Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.

PMID:
29396713
11.

The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells.

Avanzini MA, Abbonante V, Catarsi P, Dambruoso I, Mantelli M, Poletto V, Lenta E, Guglielmelli P, Croce S, Cobianchi L, Jemos B, Campanelli R, Bonetti E, Di Buduo CA, Salmoiraghi S, Villani L, Massa M, Boni M, Zappatore R, Iurlo A, Rambaldi A, Vannucchi AM, Bernasconi P, Balduini A, Barosi G, Rosti V; AGIMM Investigators.

Am J Hematol. 2018 May;93(5):615-622. doi: 10.1002/ajh.25047. Epub 2018 Feb 8.

PMID:
29359451
12.

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.

Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, Pardanani A, Hanson CA, Mannarelli C, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Aug;93(4):E93-E96. doi: 10.1002/ajh.25017. No abstract available.

13.

Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.

Salati S, Prudente Z, Genovese E, Pennucci V, Rontauroli S, Bartalucci N, Mannarelli C, Ruberti S, Zini R, Rossi C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R.

Stem Cells Dev. 2017 Dec 19. doi: 10.1089/scd.2017.0137. [Epub ahead of print]

PMID:
29258411
14.

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Bartalucci N, Calabresi L, Balliu M, Martinelli S, Rossi MC, Villeval JL, Annunziato F, Guglielmelli P, Vannucchi AM.

Oncotarget. 2017 May 22;8(57):96710-96724. doi: 10.18632/oncotarget.18073. eCollection 2017 Nov 14.

15.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
16.

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Vannucchi AM, Guglielmelli P.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):480-488. doi: 10.1182/asheducation-2017.1.480. Review.

PMID:
29222296
17.

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauroli S, Genovese E, Fanelli T, Calabresi L, Bianchi E, Salati S, Cazzola M, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators.

Blood Cancer J. 2017 Dec 8;7(12):638. doi: 10.1038/s41408-017-0010-2.

18.

Polycythemia vera and essential thrombocythemia: algorithmic approach.

Vannucchi AM, Guglielmelli P, Tefferi A.

Curr Opin Hematol. 2018 Mar;25(2):112-119. doi: 10.1097/MOH.0000000000000402.

PMID:
29194068
19.

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Mar;93(3):348-355. doi: 10.1002/ajh.24978. Epub 2017 Dec 18.

PMID:
29164670
20.

Traffic lights for ruxolitinib.

Vannucchi AM, Guglielmelli P.

Blood. 2017 Aug 31;130(9):1075-1077. doi: 10.1182/blood-2017-07-795880. No abstract available.

PMID:
28860323
21.

Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients.

Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Coltro G, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2017 Nov;92(11):1193-1197. doi: 10.1002/ajh.24882. Epub 2017 Aug 28.

PMID:
28795425
22.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA.

Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.

23.

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.

Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R.

Leukemia. 2018 Feb;32(2):438-449. doi: 10.1038/leu.2017.220. Epub 2017 Jul 12.

24.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
25.

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

Pacilli A, Fanelli T, Mannarelli C, Rotunno G, Pancrazzi A, Vannucchi AM, Guglielmelli P.

Hematol Oncol. 2018 Feb;36(1):357-359. doi: 10.1002/hon.2424. Epub 2017 May 5. No abstract available.

PMID:
28474777
26.

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.

Guglielmelli P, Pietra D, Pane F, Pancrazzi A, Cazzola M, Vannucchi AM, Tura S, Barosi G.

Leuk Res. 2017 Jul;58:63-72. doi: 10.1016/j.leukres.2017.04.006. Epub 2017 Apr 23. Review.

PMID:
28460339
27.

A life-threatening ruxolitinib discontinuation syndrome.

Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM.

Am J Hematol. 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775. Epub 2017 Jun 1. No abstract available.

PMID:
28457008
28.

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.

Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ.

Ann Hematol. 2017 Jul;96(7):1113-1120. doi: 10.1007/s00277-017-2994-x. Epub 2017 Apr 30.

29.

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.

Rontauroli S, Norfo R, Pennucci V, Zini R, Ruberti S, Bianchi E, Salati S, Prudente Z, Rossi C, Rosti V, Guglielmelli P, Barosi G, Vannucchi A, Tagliafico E, Manfredini R.

Oncotarget. 2017 Mar 28;8(13):21380-21397. doi: 10.18632/oncotarget.15226.

30.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group.

Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.

31.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

32.

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.

Bianchi E, Ruberti S, Rontauroli S, Guglielmelli P, Salati S, Rossi C, Zini R, Tagliafico E, Vannucchi AM, Manfredini R.

Int J Mol Sci. 2017 Jan 13;18(1). pii: E145. doi: 10.3390/ijms18010145.

33.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.

Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. No abstract available.

PMID:
27885272
34.

Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.

Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, Colagrande S, Castellani A, Masciulli A, Rosti V, De Stefano V, Betti S, Finazzi G, Ferrari ML, Rumi E, Ruggeri M, Nichele I, Guglielmelli P, Fjerza R, Mannarelli C, Fanelli T, Merli L, Corbizi Fattori G, Massa M, Cimino G, Rambaldi A, Barosi G, Cazzola M, Barbui T, Vannucchi AM.

Am J Hematol. 2017 Feb;92(2):187-195. doi: 10.1002/ajh.24614.

35.

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, Pacilli A, Hanson CA, Pancrazzi A, Ketterling RP, Mannarelli C, Barraco D, Fanelli T, Pardanani A, Gangat N, Vannucchi AM.

Blood Adv. 2016 Nov 22;1(1):21-30. doi: 10.1182/bloodadvances.2016000216. eCollection 2016 Nov 29.

36.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T.

Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.

37.

The prognostic impact of bone marrow fibrosis in primary myelofibrosis.

Guglielmelli P, Vannucchi AM; AGIMM Investigators.

Am J Hematol. 2016 Oct;91(10):E454-5. doi: 10.1002/ajh.24482. Epub 2016 Jul 29. No abstract available.

38.

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.

Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC.

J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Epub 2016 Jul 11.

39.

A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.

Calura E, Pizzini S, Bisognin A, Coppe A, Sales G, Gaffo E, Fanelli T, Mannarelli C, Zini R, Norfo R, Pennucci V, Manfredini R, Romualdi C, Guglielmelli P, Vannucchi AM, Bortoluzzi S.

Blood Cancer J. 2016 Jun 24;6(6):e439. doi: 10.1038/bcj.2016.47.

40.

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.

Campanelli R, Fois G, Catarsi P, Poletto V, Villani L, Erba BG, Maddaluno L, Jemos B, Salmoiraghi S, Guglielmelli P, Abbonante V, Di Buduo CA, Balduini A, Iurlo A, Barosi G, Rosti V, Massa M; AGIMM Investigators.

PLoS One. 2016 Jun 9;11(6):e0156990. doi: 10.1371/journal.pone.0156990. eCollection 2016.

41.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM.

Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4.

42.

Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms.

Loscocco GG, Mannarelli C, Pacilli A, Fanelli T, Rotunno G, Gesullo F, Corbizi-Fattori G, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Sep;91(9):E356. doi: 10.1002/ajh.24437. Epub 2016 Jul 4. No abstract available.

43.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C.

Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12.

44.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11.

45.

STAT1 activation in association with JAK2 exon 12 mutations.

Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR.

Haematologica. 2016 Jan;101(1):e15-9. doi: 10.3324/haematol.2015.128546. Epub 2015 Dec 3. No abstract available.

46.

Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.

Salati S, Zini R, Nuzzo S, Guglielmelli P, Pennucci V, Prudente Z, Ruberti S, Rontauroli S, Norfo R, Bianchi E, Bogani C, Rotunno G, Fanelli T, Mannarelli C, Rosti V, Salmoiraghi S, Pietra D, Ferrari S, Barosi G, Rambaldi A, Cazzola M, Bicciato S, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators.

Int J Cancer. 2016 Apr 1;138(7):1657-69. doi: 10.1002/ijc.29920. Epub 2015 Nov 25.

47.

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Martinaud C, Desterke C, Konopacki J, Vannucchi AM, Pieri L, Guglielmelli P, Dupriez B, Ianotto JC, Boutin L, Lataillade JJ, Le Bousse-Kerdilès MC.

Genom Data. 2015 Apr 29;5:1-2. doi: 10.1016/j.gdata.2015.04.017. eCollection 2015 Sep.

48.

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, Pancrazzi A, Vannucchi AM.

Blood Cancer J. 2015 Oct 16;5:e360. doi: 10.1038/bcj.2015.90. No abstract available.

49.

Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.

Guglielmelli P, Bisognin A, Saccoman C, Mannarelli C, Coppe A, Vannucchi AM, Bortoluzzi S.

PLoS One. 2015 Oct 15;10(10):e0140445. doi: 10.1371/journal.pone.0140445. eCollection 2015.

50.

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Guglielmelli P, Rotunno G, Pacilli A, Vannucchi AM.

Curr Hematol Malig Rep. 2015 Dec;10(4):380-7. doi: 10.1007/s11899-015-0285-y. Review.

PMID:
26431835

Supplemental Content

Loading ...
Support Center